This was the stock's third consecutive day of losses.

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 6. Analyst David Risinger ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $179.53 which represents a decrease of $-0.57 or -0.32% from the prior close of $180.1. The stock opened at $179.63 and touched a low of ...

This was the stock's second consecutive day of losses.

We recently compiled a list of the Top 20 Dividend Stocks of 2024. In this article, we are going to take a look at where ...

In an SEC filing, AbbVie ABBV has disclosed that it is lowering its previously issued guidance for 2024 adjusted earnings per ...

美国生物技术公司AbbVie(ABBV.US)下调2024财年调整後的每股盈利预测，由原先的10.9至10.94美元降至10.02至10.06美元，不及市场平均预期的10.94美元，因里程碑付款以及研究与开发成本相关的费用达到16亿美元。

Both parties will also expand research and development efforts. National Taiwan University Hospital (NTUH) and AbbVie ...

DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...

Boltwood Capital Management decreased its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 1.4% in the 4th quarter, ...